Insmed stock surges as UBS raises price target on Brinsupri launch success
PositiveFinancial Markets

Insmed's stock has seen a significant surge following UBS's decision to raise its price target, attributing this optimism to the successful launch of Brinsupri. This development is crucial as it reflects investor confidence in Insmed's growth potential and the positive reception of its new product, which could lead to increased market share and revenue.
— Curated by the World Pulse Now AI Editorial System









